Which drug first? new study aims to optimize breast cancer treatment sequence

NCT ID NCT07162259

Not yet recruiting Disease control Sponsor: Yan Xue Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at the best order to give two powerful antibody-drug conjugates (ADCs) — T-DXd and SG — to people with a common type of advanced breast cancer (HR+/HER2-). After standard hormone therapy stops working, doctors are unsure which drug to use first. The study will enroll 40 adults and track how long each sequence controls the cancer, as well as side effects. The goal is to find a smarter, personalized treatment plan.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG)
What this could lead to: If successful, this could help doctors choose the best sequence of these two drugs to extend life and improve quality of life for patients with advanced breast cancer.
What could go wrong: This is a small, early-phase study with only 40 participants, so results may not apply to everyone. The drugs can cause serious side effects, and the best sequence may not be clearly better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS

Contacts and locations

Locations

Xi'an International Medical Center Hospital

Xi'an, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.